Advertisement

Heart and Vessels

, Volume 23, Issue 4, pp 217–223 | Cite as

The current role of cardiac resynchronization therapy in reducing mortality and hospitalization in heart failure patients: a meta-analysis from clinical trials

  • Andrea Rossi
  • Giuseppe Rossi
  • Marcello Piacenti
  • Umberto Startari
  • Luca Panchetti
  • Maria-Aurora Morales
Review Article

Abstract

Many diagnostic and therapeutic advances have been reached for congestive heart failure (HF). However, despite clinical improvement and longer survival conferred by new pharmacological options, this syndrome is associated with high morbidity and mortality. Atrial-synchronized biventricular pacing (cardiac resynchronization therapy, CRT) has proven to be effective treatment in symptomatic patients with reduced left ventricular ejection fraction and electromechanical dyssynchrony. To date, many papers have been published on the role of CRT in improving quality of life, functional and neurohormonal parameters and reducing mortality and hospitalization. Eligible studies were randomized controlled trials of CRT for the treatment of chronic, symptomatic left ventricular dysfunction. Our search began dating back to 1994 and was updated to October 2006. Pooled data from the 6 selected studies showed that CRT reduced all-cause mortality by 28% (hazard ration [HR] = 0.72; 95% confidence interval [CI]: 0.60–0.86) and new hospitalizations for worsening HF by 37% (HR = 0.63; 95% CI: 0.44–0.91). This meta-analysis showed that patients with implantable cardiac defibrillators (ICDs) alone and ICD+CRT had a significant reduction of worsening HF hospitalization rate compared to no CRT-no ICD patients. Among patients with ICDs, CRT showed a slight effect on all-cause mortality reduction but no clear impact on worsening HF rehospitalization.

Key words

Cardiac resynchronization therapy Conduction disturbances Heart failure Left bundle branch block Meta-analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Braunwald E, Bristow MR (2000) Congestive heart failure: fifty years of progress. Circulation 102(suppl 4):IV14–IV23PubMedGoogle Scholar
  2. 2.
    Neglia D, Parodi O, Gallopin M, Sambuceti G, Giogetti A, Pratali L (1995) Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. Circulation 92:796–804PubMedGoogle Scholar
  3. 3.
    DE Wallis, JB O’Connell, RE Henkin, MR Costanzo-Nordin, and PJ Scanlon (1984) Segmental wall motion abnormalities in dilated cardiomyopathy: a common finding and good prognostic sign. J Am Coll Cardiol 4:674–679PubMedCrossRefGoogle Scholar
  4. 4.
    Prabhu SD (2007) Altered left ventricular-arterial coupling precedes pump dysfunction in early heart failure. Heart Vessels 22(3):170–177PubMedCrossRefGoogle Scholar
  5. 5.
    Clerico A, Fontana M, Zyw L, Passino C, Emdin M (2007) Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 53(9):1719–1720CrossRefGoogle Scholar
  6. 6.
    Taniguchi R, Sato Y, Nishio Y, Kimura T, Kita T (2006) Measurements of baseline and follow up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure of various etiologies. Heart Vessels 21:344–349PubMedCrossRefGoogle Scholar
  7. 7.
    Oh JK (2007) Echocardiography in heart failure: beyond diagnosis. Eur J Echocardiogr 8(1):4–14PubMedCrossRefGoogle Scholar
  8. 8.
    White JA, Patel MR (2007) The role of cardiovascular MRI in heart failure and the cardiomyopathies. Magn Reson Imaging Clin N Am 15:541–564PubMedCrossRefGoogle Scholar
  9. 9.
    Schinkel AF, Poldermans D, Elhendy A, Bax JJ (2007) Assessment of myocardial viability in patients with heart failure. J Nucl Med 48(7):1135–1146PubMedCrossRefGoogle Scholar
  10. 10.
    Terzi S, Sayar N, Bilsel T (2007) Tissue Doppler imaging adds incremental value in predicting exercise capacity in patients with congestive heart failure. Heart Vessels 22(4):237–244PubMedCrossRefGoogle Scholar
  11. 11.
    Stolen KQ, Kemppainen J, Kalliokoski KK, Hallsten K, Luotolanthi M, Karanko H (2004) Myocardial perfusion reserve and oxidative metabolism contribute to exercise capacity in patients with dilated cardiomyopathy. J Card Failure 10:132–140CrossRefGoogle Scholar
  12. 12.
    Cleland JG, Massie BM, Packer M (1999) Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1:41–45PubMedCrossRefGoogle Scholar
  13. 13.
    Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G, for the V-HeFT VA Cooperative Studies Group (1993) Mechanism of death in heart failure: the Vasodilator-Heart Failure Trials. Circulation 353:2001–2007Google Scholar
  14. 14.
    Barold SS, Cazeau S (2000) The first report of electrical multisite ventricular activation in humans. Pacing Clin Electrophysiol 23: 2117–2119PubMedCrossRefGoogle Scholar
  15. 15.
    Hare JM. Cardiac resynchronization therapy for heart failure (2002) N Engl J Med 346:1902–1905PubMedCrossRefGoogle Scholar
  16. 16.
    Abrahm WT, Fisher WG, Smith AL (2002) Cardiac resynchronization therapy in chronic heart failure. N Engl J Med 346:1845–1853CrossRefGoogle Scholar
  17. 17.
    Auricchio A, Ding J, Spinelli JC (2002) Cardiac resynchronization therapy restores optimal atrioventricular mechanical timing in heart failure patients with ventricular conduction delay. J Am Coll Cardiol 39:1163–1169PubMedCrossRefGoogle Scholar
  18. 18.
    Martinelli Filho M, Pedrosa AA, Costa R (2002) Biventricular pacing improves clinical behaviour and reduces prevalence of ventricular arrhythmia in patients with heart failure. Arq Bras Cardiol 78:110–113PubMedCrossRefGoogle Scholar
  19. 19.
    Yu CM, Chau E, Sanderson JE (2002) Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 105: 438–445PubMedCrossRefGoogle Scholar
  20. 20.
    Cazeau S, Leclercq C, Lavergne T (2001) Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344:873–880PubMedCrossRefGoogle Scholar
  21. 21.
    Bristow MR, Saxon LA, Boehmer J, Krueger S for the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure(COMPANION) Investigators (2004) Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advance Chronic Heart Failure. N Engl J Med 350:2140–2150PubMedCrossRefGoogle Scholar
  22. 22.
    Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352(15):1539–1549PubMedCrossRefGoogle Scholar
  23. 23.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188PubMedCrossRefGoogle Scholar
  24. 24.
    Stata Statistical Software (computer software). Release 8.0. College Station, TX: Stata Corp.Google Scholar
  25. 25.
    Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC (2001) Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344(12):873–880PubMedCrossRefGoogle Scholar
  26. 26.
    Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, Loh E, Kocovic DZ, Fisher WG, Ellestad M, Messenger J, Kruger K, Hilpisch KE, Hill MR (2003) Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107(15): 1985–1990CrossRefGoogle Scholar
  27. 27.
    Summary of Safety and Effectiveness: Guidant CONTAK CD CRT-D System [report] (2002) US Food and Drug Administration Web site. Available at: http://www.fda.gov/cdrh/pdf/p010012.html
  28. 28.
    Guidant Corp P010012. CONTAK CD and Easy Trak Lead System [transcript]. US Food and Drug Administration Center for Devices and Radiological Health Circulatory System Devices Advisory panel meeting; July 10, 2001; Gaithersburg, MD, pp 11–234. Available at: http//www.fda.gov/ohrms/dockets/ac/cdrh01.htm#CirculatorySystem. Accessed June 18, 2002Google Scholar
  29. 29.
    Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K (2003) Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 289(20):2685–2694PubMedCrossRefGoogle Scholar
  30. 30.
    McAlister FA, Ezekowitz A, Wiebe N, Rowe B, Spooner C (2004) Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure. Ann Intern Med 141:381–390PubMedGoogle Scholar
  31. 31.
    Bradley DJ, Bradley EA, Baughmann KL, Berger RD (2003) Cardiac resynchronization and death from progressive heart failure. A meta-analysis of randomised controlled trials. JAMA 289(6):730–740PubMedCrossRefGoogle Scholar
  32. 32.
    Gregoratos G, Abrams J, Epstein AE (2002) ACC/AHA/NASPE 2002 guidelines update for implantation of cardiac pacemakers and antiarrhythmia devices. Circulation 106:2145–2161PubMedCrossRefGoogle Scholar
  33. 33.
    ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol 46:1–82Google Scholar
  34. 34.
    Reuter S, Garrigue S, Barold SS, Jais P, Hocini M, Haissaguerre M, Clementy J (2002) Comparison Characteristics in responders versus nonresponders with biventricular pacing for drug-resistant congestive heart failure. Am J Cardiol 89:346–350PubMedCrossRefGoogle Scholar
  35. 35.
    Yu CM, Fung J, Zhang Q, Sanderson JE (2005) Understanding nonresponders of cardiac resynchronization therapy — current and future perspectives. J Cardiovasc Electrophysiol 16:1117–1124PubMedCrossRefGoogle Scholar
  36. 36.
    Ansalone G, Giannantoni P, Ricci P (2002) Doppler myocardial imaging to evaluate the effectiveness of pacing sites in patients receiving biventricular pacing. J Am Coll Cardiol 39:489–499PubMedCrossRefGoogle Scholar
  37. 37.
    Saxon LA, De Marco T, Schafer J (2002) Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation 105:1304–1310PubMedCrossRefGoogle Scholar
  38. 38.
    Sundell J, Engblom E, Koistinen J, Ylitalo A, Naun A, Stolen KQ, Kalliokoski R, Nekolla SG, Airaksinen KEJ, Bax JJ, Knuuti J (2004) The effects of cardiac resynchronization therapy on left ventricular function, myocardial energetics, and metabolic reserve in patients with dilated cardiomyopathy and heart failure. J Am Coll Cardiol 43:1027–1033PubMedCrossRefGoogle Scholar
  39. 39.
    Neri G, Zanco P, Zanon F, Buchberger R (2003) Effect of biventricular pacing on metabolism and perfusion in patients affected by dilated cardiomyopathy and left bundle branch block: evaluation by positron emission tomography. Europace 5(1):111–115PubMedCrossRefGoogle Scholar
  40. 40.
    Lindner O, Vogt J, Kammeier A, Wielepp P (2005) Effect of cardiac resynchronization therapy on global and regional oxygen consumption and myocardial blood flow in patients with nonischaemic and ischaemic cardiomyopathy. Eur Heart J 26(14): 1447–1448CrossRefGoogle Scholar
  41. 41.
    Knaapen P, Van Campen MLC, De Cock C, Götte M, Visser CA, Lammertsma AA, Visser FC (2004) Effects of cardiac resynchronization therapy on myocardial perfusion reserve. Circulation 110: 646–651PubMedCrossRefGoogle Scholar
  42. 42.
    Etienne Y, Mansourati J, Gilard M (1999) Evaluation of left ventricular based pacing in patients with congestive heart failure and atrial fibrillation. Am J Cardiol 83:1138–1140PubMedCrossRefGoogle Scholar
  43. 43.
    Molhoek SG, Bax JJ, Bleeker GB (2004) Comparison of response to cardiac resynchronization therapy in patients with sinus rhythm versus chronic atrial fibrillation. Am J Cardiol 94:1506–1509PubMedCrossRefGoogle Scholar
  44. 44.
    CIBIS-II Investigators and Committee (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9–13CrossRefGoogle Scholar
  45. 45.
    Packer M, Coats AJS, Fowler MB (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658PubMedCrossRefGoogle Scholar
  46. 46.
    Rogers JG, Cain ME (2004) Electromechanical associations. N Engl J Med 350:2193–2195PubMedCrossRefGoogle Scholar
  47. 47.
    Cleland JGF, Clark AL (2003) Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: too many cooks spoil the broth. J Am Coll Cardiol 42:1234–1237PubMedCrossRefGoogle Scholar
  48. 48.
    Fattore G, Landolina M, Bontempi L, Cacciatore G, Curnis A, Gulizia M, Padeletti L, Mazzei L, Tavazzi L; Gruppo di studio congiunto Federazione Italiana di Cardiologia — Assobiomedica “Valutazione del Modello CRT-Eucomed” (2005) Economic Impact of Cardiac Resynchronization Therapy in Heart Failure patients. Available evidence and evaluation of the CRT-Eucomed model for cost-effectiveness analysis. Ital Heart J Suppl 6(12):796–803PubMedGoogle Scholar

Copyright information

© Springer Japan 2008

Authors and Affiliations

  • Andrea Rossi
    • 1
  • Giuseppe Rossi
    • 1
  • Marcello Piacenti
    • 1
  • Umberto Startari
    • 1
  • Luca Panchetti
    • 1
  • Maria-Aurora Morales
    • 1
  1. 1.Electrophysiology Unit, Cardiology Department and Epidemiology and Biostatistic UnitCNR Clinical Physiology InstitutePisaItaly

Personalised recommendations